TrialFrontiers in pharmacology2026

Safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of STSA-1002, recombinant anti-human C5a fully human monoclonal antibody, in a randomized, first-in-human phase I study in healthy adults.

Yingying Fang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.